4
Changes in Ownership
ARROWHEAD PHARMACEUTICALS, INC. Filed Acc 0001628280-25-000805
Chief Financial Officer sold 45,167 shares at an average $19.77 ($893,095)
- Chief Financial Officer acquired 100,000 shares (grant or award)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Myszkowski Kenneth Allen · Chief Financial Officer
Table I: Non-derivative
5 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-01-04 | Grant or award : show line 1 in the form 10b5-1 | +100,000 | 500,600 | D | ||
| 2025-01-06 | Sale : show line 2 in the form 10b5-1 | −17,765 | $19.68 | $349,615 | 482,835 | D |
| 2025-01-06 | Sale : show line 3 in the form 10b5-1 | −9,402 | $20.10 | $188,980 | 473,433 | D |
| 2025-01-07 | Sale : show line 4 in the form 10b5-1 | −8,000 | $19.70 | $157,600 | 465,433 | D |
| 2025-01-07 | Sale : show line 5 in the form 10b5-1 | −10,000 | $19.69 | $196,900 | 455,433 | D |
| Open-market sales · 45,167 sh · avg $19.77 · $893,095 | ||||||
Loading xslF345X05/wk-form4_1736303271.xml…